Results 81 to 90 of about 24,724 (196)

Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T‐cell lymphoblastic leukemia

Clinical Case Reports, 2020
A case of an early‐relapsed high‐risk T‐ALL with high BCL‐2 expression on leukemic blasts was successfully treated with decitabine and venetoclax, achieving a CR. We suggest decitabine and venetoclax should be synergistic in BCL2‐positive ALL.
Elisabetta Zappone, Emanuele Cencini, Marzia Defina, Anna Sicuranza, Alessandro Gozzetti, Sara Ciofini, Donatella Raspadori, Bianca Mecacci, Monica Bocchia   +8 more
doaj   +1 more source

MiR-142-3p is downregulated in aggressive p53 mutant mouse models of pancreatic ductal adenocarcinoma by hypermethylation of its locus [PDF]

, 2018
Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive disease with poor prognostic implications. This is partly due to a large proportion of PDACs carrying mutations in TP53, which impart gain-of-function characteristics that promote ...
Bushell, Martin D., Godfrey, Jack D., Morton, Jennifer P., Sansom, Owen J., Wilczynska, Ania   +4 more
core   +1 more source

Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report

Journal of Immunology Research, 2014
Aberrant DNA methylation is one of the main drivers of tumor initiation and progression. The reversibility of methylation modulation makes it an attractive target for novel anticancer therapies.
Hui Fan, Xuechun Lu, Xiaohui Wang, Yang Liu, Bo Guo, Yan Zhang, Wenying Zhang, Jing Nie, Kaichao Feng, Meixia Chen, Yajing Zhang, Yao Wang, Fengxia Shi, Xiaobing Fu, Hongli Zhu, Weidong Han   +15 more
doaj   +1 more source

Converging or Crossing Curves: Untie the Gordian Knot or Cut it? Appropriate Statistics for Non-Proportional Hazards in Decitabine DACO-016 Study (AML) [PDF]

, 2015
Introduction: Among patients with acute myeloid leukemia (AML), the DACO-016 randomized study showed reduction in mortality for decitabine [Dacogen® (DAC), Eisai Inc., Woodcliff Lake, NJ, USA] compared with treatment choice (TC): at primary analysis the
De Porre, Peter, Diels, Joris, Güntert, Andreas, Lange, Ansgar, Tapprich, Christoph, Thilakarathne, Pushpike, Tomeczkowski, Jörg, Xiu, Liang   +7 more
core   +3 more sources

Real‐World Analysis of Outcomes of Venetoclax+Azacitidine Versus 7+3 Induction in Acute Myeloid Leukemia

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Background Venetoclax plus azacitidine (V+A) is standard for older, intensive‐ineligible patients with acute myeloid leukemia (AML). Its expanding use in younger, curative‐eligible adults lacks comparative evidence against conventional 7+3 induction, raising uncertainty about potential survival compromise.
Nehemias Guevara Rodriguez, Noemy Coreas Mercado, Syeda Ashna Fatima Kamal, Sandeep Beesabathina, Dawson Foster, Nabeel Rajeh, Ranju Kunwor   +6 more
wiley   +1 more source

Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma [PDF]

, 2016
Hepatocellular carcinoma (HCC) is a deadly malignancy characterized at the epigenetic level by global DNA hypomethylation and focal hypermethylation on the promoter of tumor suppressor genes.
Azab, M., Cannito, S., CAPPELLO, Francesco, Jueliger, S., Lo Re, O., Lyons, J., Pata, I., Pata, P., Pazienza, V., Peyrou, M., RAPPA, Francesca, Shkolnaya, M., Taverna, P., Villarroya, F., Vinciguerra, M.   +14 more
core   +2 more sources

Isocitrate Dehydrogenase‐Mutant Astrocytomas: Risk Stratification and Therapeutic Advance

MedComm, Volume 7, Issue 4, April 2026.
This graphical abstract synthesizes the core logic of our revised review by linking integrated diagnosis, risk stratification, and trajectory‐based management in IDH‐mutant astrocytomas across CNS WHO Grades 2–4. It highlights lineage‐defining molecular classification (IDH mutation with core co‐alterations), integrated histomolecular grading, and key ...
Shepeng Wei, Xuxu Xu, Jing Bao, Zhenjiang Pan   +3 more
wiley   +1 more source

Epigenetic mechanisms and therapeutic innovations in chronic pain‐associated neuropsychiatric co‐morbidities

British Journal of Pharmacology, Volume 183, Issue 7, Page 1313-1340, April 2026.
Abstract Chronic pain, marked by nociceptive sensitization and maladaptive neuroplasticity, affects 30% of the global population with escalating socioeconomic burdens. Epidemiological data show a 2‐3‐fold increase in neuropsychiatric co‐morbidities among individuals with chronic pain, where epigenetic dysregulation serves as a key mechanism linking ...
Kai Zhang, Sijia Zhu, Na Xing, Zhen Zhou, Jiayi Chen, Tianen Si, Mingrui Li, Lin Jia, Yousef Rastegar‐Kashkooli, Tom J. Wang, Wei Zhu, Jing Li, Chao Jiang, Junmin Wang, Moxin Wu, Xiaoping Yin, Weidong Zang, Jian Wang, Songxue Su   +18 more
wiley   +1 more source

Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights [PDF]

, 2010
Prognostic markers, such as NPM1, Flt3-ITD, and cytogenetic abnormalities have made it possible to formulate aggressive treatment plans for unfavorable acute myeloid leukemia (AML).
Xiongpeng Zhu, Yuehua Ma, Delong Liu
core   +2 more sources

Compound Library Screening Identified Cladribine as a Novel Radiosensitizer for Prostate Cancer

Cancer Science, Volume 117, Issue 4, Page 1136-1147, April 2026.
The combination of cladribine and irradiation significantly suppressed the growth of DU145‐derived tumors compared with the DMSO plus irradiation group in the mouse model. In addition, it also elevated the percentage of γH2AX‐positive cells after irradiation.
Toshiki Oka, Koji Hatano, Shohei Katsuki, Tomohiro Kanaki, Shunsuke Inoguchi, Masaru Tani, Akihiro Yoshimura, Yuki Horibe, Yutong Liu, Nesrine Sassi, Yohei Okuda, Akinaru Yamamoto, Toshihiro Uemura, Gaku Yamamichi, Yu Ishizuya, Takuji Hayashi, Yoshiyuki Yamamoto, Taigo Kato, Atsunari Kawashima, Keisuke Tamari, Bangzhong Lin, Akiyoshi Tani, Kazutake Tsujikawa, Yutaka Takahashi, Kazuhiko Ogawa, Shawn E. Lupold, Norio Nonomura   +26 more
wiley   +1 more source